Medpacto: Material Management Matter: Approval of IND Amendment for Phase 1/2 Clinical Trial of Vactosertib Monotherapy in Patients with Relapsed, Refractory, or Progressive Osteosarcoma (MFDS)
AI reading
★★★ Bullish · Material event
Approval of IND Amendment for Vactosertib Monotherapy Clinical Trial in Osteosarcoma Patients
An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).
Other filings by Medpacto
- 09.18 ★★★ Application for IND Amendment for Vactosertib Clinical Trial in Osteosarcoma Patients
- 09.18 ★★ [Amended] Material Management Matter: Application for IND Amendment for Phase 1/2 Clinical Trial of Vactosertib Monotherapy in Patients with Relapsed, Refractory, or Progressive Osteosarcoma (MFDS)
- 09.18 ★★ [Amended] Material Management Matter: Approval of IND Amendment for Phase 1/2 Clinical Trial of Vactosertib Monotherapy in Patients with Relapsed, Refractory, or Progressive Osteosarcoma (MFDS)
For information only. Not investment advice.